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INTRODUCTION
In treatments of neuroblastoma (NB) and adult neuroendocrine tumors (NET), surgery is the first-line therapy with the aim of achieving a complete cure 1,2 . If radical surgery is not 50 feasible, multimodal treatment options include surgery, chemotherapy, external beam radiotherapy (EBRT) and molecular radiotherapy (MRT) 3 . 131 I-mIBG therapy is administered for inoperable pheocromocytomas, paragangliomas, carcinoid tumors, stage III or IV relapsed or primary refractory NBs and metastatic or recurrent medullary thyroid cancers 4 . The number of patients treated with 131 I-mIBG is usually limited compared to the total number of NB and 55 NET patients as 131 I-mIBG therapy is frequently considered only when other treatment modalities have been exhausted.
During the last two decades several studies have been published on the use of 131 I-mIBG for NB and NET treatments 5-12 , and guidelines have been provided by the European Association of Nuclear Medicine (EANM) 4 . The administered activity is most commonly prescribed using 60 fixed activities 13, 14 or a specified activity per patient mass [15] [16] [17] [18] or per body surface 19 . Some studies have shown an improved treatment outcome with increased administered activities 20, 21 . In NB treatments, the most established schedule is given by Gaze et al. 17 . In this protocol, two treatment administrations separated by a fortnight are given where the first is prescribed as activity per body mass (444 MBq/kg), and the second is tailored to deliver a 65 whole-body absorbed dose of 4 Gy in total for the two administrations. In NET treatments, where dosimetric data are still limited 22 , established schedules are currently lacking, although in principle a similar dosimetry-based approach could be adopted. In both NB and NET treatments, there is a need to compile experience and working knowledge of clinically obtained whole-body absorbed doses per unit of administered activity. Such information can 70 be used to improve estimates of the activity to administer at the stage when dosimetric data are lacking, such as for the first activity administration in a fractionated schedule.
Hematologic toxicity is dose limiting in 131 I-mIBG therapy [23] [24] [25] . When activities above 444
MBq/kg are administered, harvesting of autologous tumor-free, hematopoietic stem cells must be performed before treatment 26 . In the schedule by Gaze et al. 17 , stem-cell rescue is 75 performed after approximately four weeks from the first administration, when the activity in the body has decreased below 30 MBq. When stem cells are not available, it must be ensured that the administered activity does not exceed levels that may induce non-tolerable redmarrow absorbed doses. Here, the use of whole-body dosimetry as a surrogate for red-marrow dosimetry has been established 27 . This obviates the need for repeated blood sampling, which 80 is considered invasive, particularly in children. However, as pointed out in a recent review 12 , no study has yet focused on the difference between whole-body and red-marrow absorbed doses.
This study reports on dosimetric results from 131 I-mIBG NB and NET treatments in the Gurutzeta-Cruces University Hospital during the last six years. The aim is to investigate 85 absorbed doses for whole body and red marrow. A further aim is to propose a simple method for determining the activity to administer at the stage when dosimetric data are not available for the individual patient, based on data acquired in this study and in the context of other published studies. The recommendations of the EANM 28 have been taken into account in the composition of the paper. 90
METHODS

2.A. Patient population and administrations
NB treatments
Nine patients (six male and three female, age 3y−22y) with relapsed stage-4 NB were 95
included. Three patients were given two treatments separated by more than one year, with the result that twelve treatments were considered in total. Further on, NB treatments are denoted TNB1-TNB9, with postscripts a and b to indicate repeated treatment of the same patient. A summary of treatment data including patient mass, mp, administered activity, Aadm, and performed measurements is given in Table 1. Treatments TNB1a, TNB2, TNB3, TNB4, TNB6a,  100 TNB7 and TNB8 were performed following the schedule by Gaze et al. 17 . Treatments TNB1b, TNB5, TNB6b, TNB4 and TNB9b were performed without concomitant chemotherapy and stem cell support in one or two fractions (see Table 1 ) aiming at giving a whole-body absorbed dose, Dwb, of 2 Gy. Treatment TNB9a was performed with concomitant chemotherapy and stem cell support but did not follow the schedule by Gaze et al. 17 
NET treatments 115
Six NET patients were included (five female and one male, age 21y−80y). One patient was treated twice, so in total seven treatments were considered. Further on, NET treatments are denoted TNET1-TNET6, with postscripts a and b to indicate repeated treatment. A summary of treatment data is given in Table 2 . For TNET2, TNET3, TNET5, TNET6a and TNET6b, a pretreatment dosimetry study was also performed approximately one month before treatment. 120 from their parents in the case of children, was obtained.
2.B. Data acquisition and activity quantification
Dose-rate measurements were performed during the time as inpatients for estimation of the whole-body time-activity curve (see Tables 1 and 2 The height of the detector in relation to the floor was held constant with reference to an external mark, and all measurements were made by trained staff. The first measurement was performed immediately after the administration to obtain a reading corresponding to the total 140
Aadm. Remaining measurements were made approximately every two hours during the first day, every four hours during the second day and every six hours during the remaining days, aiming at performing acquisitions after bladder voids. In total this yielded approximately 20 time points for each treatment. The signal-to-noise ratio, estimated by dividing the patient readings with the variability in background readings, was above 20 in all measurements, and 145 dead-time effects were negligible. A sequence of whole-body time-activity values, Awb(t), was determined from the anterior and posterior readings, RA(t) and RP(t), for each patient-detector distance according to
where r(t) were the relative values obtained from measurement, with r(0) =1. The Awb(t)
values from measurements at 1 m and 2 m differed less than 5%, and the average value was 150 therefore used. A dose calibrator, Capintec CRC®-15R, (Capintec, Inc Ramsey, NJ, USA), was used for measurements of Aadm.
Planar imaging using a gamma camera was employed to estimate the whole-body timeactivity curve in NET pre-treatment dosimetric studies, and also in two NB treatments for comparison to dose-rate meter derived values (Tables 1 and 2 Blood sampling was performed in six NB treatments, five NET pre-treatment studies, and one NET treatment, for the purpose of red-marrow dosimetry (see Tables 1 and 2 ). For NB patients blood sampling was performed at a few minutes, 6 h, 24 h, 48 h, 72 h, and 96 h or 115 h after injection, whereas for NET patients, blood sampling was made at a few minutes, 6 h, 24 h, 48 h, and 120 h. Blood samples of 1 ml or 2 ml volume were prepared using a pipette, 175 and were then allowed to decay to avoid dead-time effects. Measurements were performed using a calibrated γ-well counter 1282 Compugamma CS LKB Wallac (Melbourne, Australia). The activity concentration was determined by dividing the obtained count rate by a pre-determined calibration factor and the sample volume.
2.C. Dosimetric calculations 180
Dwb were calculated following the standard MIRD methodology 30 
, as described in Appendix
A. Blood-based calculation of red-marrow absorbed dose, Drm, was carried out according to procedures in the EANM guidelines 26 and to the MIRD formalism, including source terms from activity in the red marrow and in the remainder of the body for the self-and crossabsorbed dose, respectively, as described in Appendix B. Additionally, the method described 185 by Traino et al. 31 was used.
The standard deviations in Dwb and Drm were estimated by uncertainty propagation 32 , as described in Appendix C. For both Dwb and the whole-body residence time, τwb, the relative standard deviation was estimated to be 20%. The main contribution to Drm was the crossabsorbed dose from the remainder of the body, and the relative standard deviation for Drm 190 was thus also estimated to be 20%. These uncertainties are in line with values suggested by others 33, 34 .
2.D. Hematologic toxicities
The post-therapy platelet, neutrophil and leukocyte nadir was obtained in NET treatments in order to study hematologic toxicity. The grade of toxicity was analyzed according to the 195 Common Terminology Criteria of Adverse Events (CTCAE), version 3 35 (available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf). In NB treatments the grade of hematologic toxicity was not quantified, since in the majority of treatments the intent was aplasia. Table 3 are based on probe-based dose-rate measurements. Figure 1 shows a comparison between Awb (t) derived from dose-rate measurements and gamma camera images for TNB3. Differences between values obtained from imaging and dose-rate measurements were within 10% for both TNB3 and TNB9b. 215 245 Table 6 shows Drm/Aadm obtained for pre-treatment dosimetric studies. In TNET1 and TNET4 blood samples could not be obtained. Following the procedure by Traino et al. 31 lower values for Drm were obtained, but within 10% of values of Drm in Table 6 . The self-absorbed dose was between 14% and 18% of the total Drm. For TNET5, Drm was also calculated during the first treatment administration. The value of Drm/Aadm obtained was 0.10±0.02 Gy/GBq, which 250 was thus in agreement with that of the pre-treatment study. 
3.A. NB treatments
3.B. NET treatments
260
The grade of toxicity in NET treatments is shown in Table 7 . No correlation between the grade of toxicity in platelets, leukocytes and neutrophils and Dwb or Drm was found. However, there was a tendency that toxicity was more pronounced for elderly patients than for younger ones. None None None 28 Table 7 . Grade of toxicity in NET treatments. As seen in Table 3 , a similar τwb was obtained in NB treatments, except for TNB2. If inserting 275 one single value of τwb into Eq. (A1), the ratio Dwb/Aadm follows a power dependence with mp.
265
3.C. Analysis of dosimetric results for NBs and NETs
Using the mean value of τwb obtained in this study, the following Equation was obtained:
in unit of Gy/GBq. Results of Eq. (2) were compared to results from previously published studies, using data of Dwb/Aadm for NB treatments as retrieved from the study by Toporski et 280 al. 11 performed at Lund University Hospital, Sweden, and from the study by Buckley et al. 25 performed at Royal Marsden Hospital, UK. To rule out inconsistencies in calculation methods among centers, a small comparison exercise was undertaken sharing three sets of acquired time-dose rate data. Dwb were calculated at each of the three centers, with results obtained of within 10% from the mean value, thus supporting a combined data analysis. Figure 3 shows 285 Eq. (2) in relation to data acquired in this study, and combined with data from Toporski et al. 11 and Buckley et al. 25 . Regarding NET (Table 5) 
DISCUSSION
In NB and NET treatments with 131 I-mIBG, very different schedules have been reported [13] [14] [15] [16] [17] [18] [19] , 310 often using prescriptions in terms of a fixed activity or a predetermined activity per body mass. For treatment of NB, the most widely used dose scheduling approach is that of Gaze et al. 17 and is based on planning of Dwb using two treatment fractions. In NET treatments, such established schedules are still lacking, although a similar approach could be adopted to tailor Dwb with regard to the risk of inducing hematologic and non-hematologic toxicities. 315
The analysis of patient data by Eqs. In this study, Dwb/Aadm values are higher and show a wider range for NB than for NET treatments consistent with those reported in Sudbrock et al. 9 and Hindorf et al. 27 . Figures 3   and 4 , based on Eqs. (2) and (3), respectively, provide an explanation for those results based 335 on the dependence of Dwb/Aadm on mp. It is important to note that Eqs. (2) and (3) are not intended as replacement for dosimetry-based schedules, since τwb of individual patients may vary to a high degree. For instance, in TNB2, the patient (mp=13kg) suffered from a nephropathy and the obtained Dwb/Aadm value was lower that the value obtained by Eq. (2), as seen in Figure 3 and Table 3 . In TNET4 and TNET5 (mp=49 kg and 80 kg, respectively), patients 340 had an extensive tumor burden and their Dwb/Aadm values were notably higher than the value obtained from Eq. (3), as seen in Figure 4 (left) and Table 5 .
Thus, whole-body dosimetry measurements during the first administration would still be necessary in order to calculate the activity to deliver in the second administration. Dwb is generally used as a surrogate for Drm in 131 I-mIBG therapy. In this study, values of Drm were found to be between 60% and 70% of Dwb, which is reasonable considering the modest 350 contribution of the self-absorbed dose and the values for the Swb←wb/Srm←wb ratio. In patients in whom there is red-marrow and/or bone uptake, it is generally recommended to use imagingbased estimates of Drm 26, 36, 37 , as blood-based values may underestimate the real value.
However, results from the blood-based method may be a good approximation when red-marrow or bone uptake is localized to small regions 36 . For the patients in this study where 355 red-marrow dosimetry was performed, in five patients (TNB9a, TNB9b, TNET2, TNET6a and TNET6b) uptake in red marrow or bone was seen in separate SPECT-CT studies, but involved less than 5% of the total marrow volume, thus justifying the use of the blood-based dosimetry method.
A further analysis was performed by comparison to the results from Matthay et al. 22 The grade of hematologic toxicity (Table 7) shows that caution must be exercised for high-375 activity treatments. Unlike that of Buckley et al. 25 , this study found no correlation between the grade of hematologic toxicity and Dwb. Notably, in TNET3, a Dwb of 1.3 Gy was delivered but the patient suffered grade-4 toxicity (platelets, leukocytes and neutrophils) and in TNET4, the patient with multiple bone metastases received a Dwb of 4.1 Gy but did not exceed grade-3 toxicity. As with Dwb, no correlation was found between the grade of hematologic toxicity and 380
Drm. There are several possible reasons for the lack of correlation found between Drm and Dwb with hematologic toxicity. Among those are the low number of patients included, the different ages of patients, the diversity of NETs (pheochromocytoma, carcinoid tumor and paraganglioma), prior hematotoxic treatments, and the way the cross-absorbed dose to the red marrow is calculated in Eq. (B1). Regarding the latter point, if the activity in the remainder of 385 the body is mainly localized in tumors, then its contribution to Drm is likely to be heterogeneous with an important proportion of the red marrow receiving absorbed doses below tolerance values. In a study of hematological toxicity in EBRT performed by Petersson et al. 38 , it was shown that the severity of toxicity correlated with the volume fraction of red marrow that was irradiated. In this study the volume distribution of Drm was not addressed, 390 and so, depending on the tumor burden, two treatments with the same value of Drm obtained from Eq. (B1) may show different hematologic toxicity. These results indicate the need to improve currently used methods for red-marrow dosimetry in MRT, taking the heterogeneous distribution of internal absorbed doses into account. 395
CONCLUSIONS
In treatments with 131 I-mIBG, the activity to administer in order to give a prescribed Dwb varies from patient to patient. In this study, consistent values of Dwb/Aadm were obtained when determined for different administrations in the same patient, whereas a considerable variation 400 was seen among patients. These results thus support the use of absorbed-dose planning for multiple-fraction treatment. Moreover, an expression was proposed for prescription of the activity for the first administration, which takes into account the dependence of Dwb/Aadm on mp, to be used at the stage when dosimetric data for the individual patient have not yet been measured. For red marrow, Drm was found to be between 60% and 70% of Dwb. 405
where wb Ã is the cumulated activity in the whole body (wb) and Swb←wb is the whole-body absorbed dose per cumulated activity in wb, calculated according to Cristy et al. 39 where coefficient ai is the initial value for component i and i is the effective half-life, in unit h -1 , for the respective component 25 . The value of n was set to 3 and 2, for dose-rate measurements and gamma-camera imaging, respectively.
APPENDIX C: ESTIMATION OF UNCERTAINTIES 440
The standard deviation in Dwb was determined by uncertainty propagation through Eq. (A1), considering only the uncertainty in wb Ã as determined from standard deviations of Aadm and τwb. The relative standard deviation of Aadm was estimated to be 5%. The uncertainty in τwb (Eq. (A3)) depended on the uncertainty in the parameters ai and i, which in turn depended on the uncertainty of r(t) in Eq. (1), and the number of data points used for curve fitting. The 445 standard deviation in r(t), r, was calculated by uncertainty propagation through the expression for r(t). For dose rate measurements, uncertainties in RA(t) and RP(t) were primarily related to measurements of patient-detector distance and fluctuations in the measured value, for which the relative standard deviations were estimated to be 5% in both cases. For gamma camera measurements, the major sources of uncertainty in RA(t) and RP(t) 450 were assumed to be operator dependency in delineation of the whole-body ROI, and a variability in the accuracy of Eq. (1) due to different attenuation and scatter conditions for different times after administration. The relative standard deviations of these effects were estimated to be 7% and 10%, respectively. The uncertainty contribution to τwb from curve fitting was determined from simulated, typical time-retention curves, consisting of three 455 components. This simulation was performed by generating time-series of values r(t) using an analytical expression, and then replacing each data point with a value which was sampled from a normal distribution with standard deviation r. One hundred simulations were performed, giving a relative standard deviation for τwb of approximately 19% for both measurement techniques. The relative standard deviations in wb Ã and thus in Dwb, were 460 approximately 20%. Because the main contribution to Drm was the cross-absorbed dose, the uncertainty in Drm was estimated to be approximately equal to the uncertainty in Dwb.
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